EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, and Anti-Inflammatory Activity Evaluation of Novel thieno[2,3- d ]Pyrimidin-4(3 H )-One-Based NLRP3 Inflammasome Inhibitors

Yuqi Jiang iD, Simin Sun iD, Jinyu Liu, Jiayue Huang, Huimin Wang, Tongqiang Xu, Leyan Wang, Zhendi Shi, Xiaoyang Li iD

Journal of Medicinal Chemistry · 2026

DOI: 10.1021/acs.jmedchem.6c02162 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Yuqi Jiang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Marine Drug, Chinese Ministry of Education, Molecular Synthesis Center, Center for Targeted Protein Degradation and Drug Discovery,…. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes, Drug Design, Pyrimidinones. Die Arbeit nennt 68 Literaturangaben. Gefördert von: Ocean University of China, Natural Science Foundation of Shandong Province, National Natural Science Foundation of China (NSFC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The NLRP3 inflammasome plays a critical role in the pathogenesis of inflammatory diseases and has emerged as a promising therapeutic target. Our preliminary studies revealed that istradefylline, an anti-Parkinsonian agent, exhibits moderate NLRP3 inhibitory activity. Furthermore, we optimized the structure and activity of istradefylline, leading to a series of thienobenzo[d]pyrimidin-4(3H)-one-based NLRP3 inhibitors. Among them, compound L22 exhibited the most potent inhibitory activity (IC50 = 0.16 μM), which was 10-fold stronger than istradefylline (1.81 μM). L22 directly binds to the NLRP3 NACHT domain (KD = 357.8 nM), inhibiting inflammasome assembly and activation. L22 is an orally bioavailable NLRP3 inhibitor, and significantly alleviated symptoms in a DSS-induced ulcerative colitis model. Acute and subacute toxicity studies indicated that L22 possesses a favorable safety profile. These results not only provide compelling evidence for developing more potent NLRP3 inhibitors based on this scaffold but also offer an optimizable lead compound for colitis treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesDrug DesignPyrimidinonesAnti-Inflammatory AgentsPyrimidinesAnimalsStructure-Activity RelationshipMiceHumansMice, Inbred C57BLMaleColitis

Stichwörter der Autor:innen

NLRP3 inhibitorsanti-inflammatorycolitisinflammasomeistradefyllinepyroptosisthienobenzo[d]pyrimidin-4(3H)-one

Substanzen

NLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesPyrimidinonesAnti-Inflammatory AgentsPyrimidines

Autor:innen und Institutionen

  • Key Laboratory of Marine Drug, Chinese Ministry of Education, Molecular Synthesis Center, Center for Targeted Protein Degradation and Drug Discovery, and School of Medicine and Pharmacy, Ocean University of China, 5 Yus…
  • Laboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, Qingdao266237Shandong, China.
  • Marine Biomedical Research Institute of Qingdao, Qingdao, Shandong266071, P. R. China.

ORCID-Profile: Yuqi Jiang, Simin Sun, Xiaoyang Li

Förderung

  • Ocean University of China
  • Natural Science Foundation of Shandong Province
  • National Natural Science Foundation of China (NSFC)
  • Science Foundation for Excellent Young Scholars of Shandong Province
  • Natural Science Foundation of Qingdao Municipality
  • Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China

Zitieren

APA

Jiang, Y., Sun, S., Liu, J., Huang, J., Wang, H., Xu, T., Wang, L., Shi, Z., & Li, X. (2026). Design, Synthesis, and Anti-Inflammatory Activity Evaluation of Novel thieno[2,3- d ]Pyrimidin-4(3 H )-One-Based NLRP3 Inflammasome Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c02162

Vancouver

Jiang Y, Sun S, Liu J, Huang J, Wang H, Xu T, et al. Design, Synthesis, and Anti-Inflammatory Activity Evaluation of Novel thieno[2,3- d ]Pyrimidin-4(3 H )-One-Based NLRP3 Inflammasome Inhibitors. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c02162

BibTeX
@article{Jiang2026,
  author = {Jiang, Yuqi and Sun, Simin and Liu, Jinyu and Huang, Jiayue and Wang, Huimin and Xu, Tongqiang and Wang, Leyan and Shi, Zhendi and Li, Xiaoyang},
  title = {Design, Synthesis, and Anti-Inflammatory Activity Evaluation of Novel thieno[2,3- d ]Pyrimidin-4(3 H )-One-Based NLRP3 Inflammasome Inhibitors},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.6c02162}
}
Kostenlos starten →